Recently, according to data from Nielsen, their convenience store report data for U.S. in May showed that the electronic cigarette brand VUSE by British American Tobacco (BAT) slightly increased its market share from 41.8% to 42.3%, while JUUL, ranked second, saw a decrease in market share from 26% to 25.6%.
It has been reported that Nielsen's data primarily comes from large chain stores. Over the past 12 months, there has been a decrease in consumer demand for tobacco products, primarily due to inflation and recent price increases in traditional cigarettes.
As a result of the FDA issuing a marketing denial order against JUUL, they are currently involved in legal proceedings. This has provided momentum for the market share growth of VUSE. While NJOY, which is ranked third, has seen an increase in market share from 2.7% to 2.8%, and Blu, which is owned by Imperial Tobacco, has experienced a decline in market share from 1.4% to 1.3%.
Altria has announced that it has divested its minority stake in JUUL, paving the way for its full acquisition of NJOY. Altria had just previously completed the acquisition of NJOY for $2.75 billion and plans to launch NJOY ACE in 70,000 retail stores across the United States.
For comparison, according to Nielsen's May report, JUUL's sales decreased by 22.3%, while VUSE increased by 19.3%. NJOY decreased by 5.3%, and Blu saw a decrease of 31.7%.
References:
Reynolds' Vuse continues to stretch market share lead over Juul
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
